{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T21:40:25Z","timestamp":1794778825807,"version":"4.9.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017037","name":"Cepheid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eururo.2025.03.018","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:22:52Z","timestamp":1745562172000},"page":"23-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non\u2013muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Thomas","family":"Dreyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Fabrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessn","family":"Azawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.03.018_b0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","article-title":"Recurrence mechanisms of non-muscle-invasive bladder cancer \u2014 a clinical perspective","volume":"19","author":"Teoh","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0025","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0030","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s11136-016-1264-z","article-title":"Anxiety and depression analyses of patients undergoing diagnostic cystoscopy","volume":"25","author":"Seklehner","year":"2016","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2025.03.018_b0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejso.2013.11.003","article-title":"Transuretral resection of the bladder (TURB): Analysis of complications using a modified Clavien system in an Italian real life cohort","volume":"40","author":"De Nunzio","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2025.03.018_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.urolonc.2024.01.025","article-title":"Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer","volume":"42","author":"Benderska-S\u00f6der","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.018_b0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.juro.2017.09.141","article-title":"Development of a 90-minute integrated noninvasive urinary assay for bladder cancer detection","volume":"199","author":"Wallace","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.eururo.2018.11.055","article-title":"Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer","volume":"75","author":"van Valenberg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/bju.15418","article-title":"Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert\u00ae Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer","volume":"128","author":"Cowan","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.018_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eururo.2025.03.018_b0065","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eururo.2025.03.018_b0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta\u2013T1 urothelial bladder cancer patients treated with 1\u20133 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0075","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.03.018_b0080","unstructured":"Danish Bladder Cancer Group. Danish bladder cancer guidelines. https:\/\/blaerecancerinfo.dk\/sundhedspersonale\/behandling\/retningslinjer-for-behandling\/."},{"key":"10.1016\/j.eururo.2025.03.018_b0085","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1245\/s10434-016-5763-5","article-title":"Anticipatory positive urine tests for bladder cancer","volume":"24","author":"Gopalakrishna","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2025.03.018_b0090","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic accuracy of novel urinary biomarker tests in non\u2013muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.018_b0095","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and surveillance of bladder cancer using urine tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2025.03.018_b0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2023.07.014","article-title":"Field cancerization is associated with tumor development, T-cell exhaustion, and clinical outcomes in bladder cancer","volume":"85","author":"Strandgaard","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","volume":"2","author":"Lee","year":"2020","journal-title":"Clinicoeconom Outcomes Res"},{"key":"10.1016\/j.eururo.2025.03.018_b0110","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00345-018-2550-x","article-title":"Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories","volume":"37","author":"Mossanen","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1464-410X.2005.05249.x","article-title":"The economic consequences of prostate and bladder cancer in the UK","volume":"95","author":"Sangar","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.018_b0120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3050","article-title":"Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non\u2013muscle-invasive bladder cancer among older adults, 2004\u20132013","volume":"5","author":"Bree","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.03.018_b0125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.urology.2009.12.079","article-title":"Regional differences in early stage bladder cancer care and outcomes","volume":"76","author":"Skolarus","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.03.018_b0130","first-page":"3946","article-title":"Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety","volume":"56","author":"Dreyer","year":"2022","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2025.03.018_b0135","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:22:56Z","timestamp":1749662576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0302283825001915"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.018","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non\u2013muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}